Literature DB >> 23158871

Juvenile-onset motor neuron disease caused by novel mutations in β-hexosaminidase.

Tyler Mark Pierson1, Paola A Torres, Bei-Jin Zeng, Allan M Glanzman, David Adams, Richard S Finkel, Don J Mahuran, Gregory M Pastores, Gihan I Tennekoon, Edwin H Kolodny.   

Abstract

A 12 year-old female presented with a seven-year history of progressive muscle weakness, atrophy, tremor and fasciculations. Cognition was normal. Rectal biopsy revealed intracellular storage material and biochemical testing indicated low hexosaminidase activity consistent with juvenile-onset G(M2)-gangliosidosis. Genetic evaluation revealed compound heterozygosity with two novel mutations in the hexosaminidase β-subunit (c.512-3 C>A and c.1613+15_1613+18dup). Protein analysis was consistent with biochemical findings and indicated only a small portion of β-subunits were properly processed. These results provide additional insight into juvenile-onset G(M2)-gangliosidoses and further expand the number of β-hexosaminidase mutations associated with motor neuron disease.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23158871      PMCID: PMC3601980          DOI: 10.1016/j.ymgme.2012.10.023

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  20 in total

1.  Molecular genetics of the beta-hexosaminidase isoenzymes: an introduction.

Authors:  E H Kolodny
Journal:  Adv Genet       Date:  2001       Impact factor: 1.944

2.  An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants).

Authors:  Joe T R Clarke; Don J Mahuran; Swati Sathe; Edwin H Kolodny; Brigitte A Rigat; Julian A Raiman; Michael B Tropak
Journal:  Mol Genet Metab       Date:  2010-09-17       Impact factor: 4.797

3.  An adaptable standard for protein export from the endoplasmic reticulum.

Authors:  R Luke Wiseman; Evan T Powers; Joel N Buxbaum; Jeffery W Kelly; William E Balch
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

4.  Characterization of a variant of beta-hexosaminidase: "hexosaminidase Paris".

Authors:  J C Dreyfus; L Poenaru; M Vibert; N Ravise; J Boue
Journal:  Am J Hum Genet       Date:  1977-05       Impact factor: 11.025

Review 5.  The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.

Authors:  Gustavo H B Maegawa; Tracy Stockley; Michael Tropak; Brenda Banwell; Susan Blaser; Fernando Kok; Roberto Giugliani; Don Mahuran; Joe T R Clarke
Journal:  Pediatrics       Date:  2006-10-02       Impact factor: 7.124

Review 6.  Biochemical consequences of mutations causing the GM2 gangliosidoses.

Authors:  D J Mahuran
Journal:  Biochim Biophys Acta       Date:  1999-10-08

Review 7.  The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis.

Authors:  Lauren C Frey; Steven P Ringel; Christopher M Filley
Journal:  Arch Neurol       Date:  2005-06

8.  Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.

Authors:  Gustavo H B Maegawa; Michael Tropak; Justin Buttner; Tracy Stockley; Fernando Kok; Joe T R Clarke; Don J Mahuran
Journal:  J Biol Chem       Date:  2007-01-21       Impact factor: 5.157

9.  Spinocerebellar degeneration: hexosaminidase A and B deficiency in two adult sisters.

Authors:  J G Oonk; H J van der Helm; J J Martin
Journal:  Neurology       Date:  1979-03       Impact factor: 9.910

10.  Progressive cerebellar ataxia, spasticity, psychomotor retardation, and hexosaminidase deficiency in a 10-year-old child: juvenile Sandhoff disease.

Authors:  P M MacLeod; S Wood; J E Jan; D A Applegarth; C L Dolman
Journal:  Neurology       Date:  1977-06       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.